PET/MR imaging offers comparable diagnostic image quality and tumor delineation in staging of lung cancer to PET/CT - with less radiation exposure.
PET plus MR imaging offers comparable diagnostic image quality and tumor delineation in staging of lung cancer to PET plus CT - with less radiation exposure to the patient, researchers reported in a study published in the journal Radiology.
Researchers from Eberhard-Karls University in Tübingen, Germany, studied 10 patients who were suspected to have or were diagnosed with bronchial carcinoma. The patients, aged 38 to 73, underwent fluorine 18 fluorodeoxyglucose (FDG) PET/CT, followed immediately by whole-body MR/PET imaging with a new hybrid whole-body system (3.0-T MR imager with integrated PET system).
Upon review of the results of the MR/PET, the researchers found nine of the 10 lesions showed pronounced FDG uptake. One lesion was morphologically suspicious for CT and MR imaging, but showed no FDG uptake.
Tumor-to-liver ratios were also calculated and compared between the two examinations. There was a significant correlation regarding the tumor-to-liver ratio with identical TNM scores for seven patients.
“MR/PET imaging of the lung is feasible and provides diagnostic image quality in the assessment of pulmonary masses,” the authors wrote. “Similar lesion characterization and tumor stage were found in comparing PET/CT and MR/PET images in most patients.”
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.